Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023
Surrozen, Inc. (Nasdaq: SRZN) will report its Q4 and full year 2022 financial results on March 22, 2023, after the U.S. markets close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Surrozen, Inc. (Nasdaq: SRZN) will report its Q4 and full year 2022 financial results on March 22, 2023, after the U.S. markets close. The company will also provide a corporate and pipeline progress update during a live audio webcast at 4:30 PM ET. Interested participants can access the webcast via the Investor website. Surrozen is a clinical-stage biotechnology firm focused on developing drug candidates that selectively modulate the Wnt pathway, targeting conditions like inflammatory bowel disease, severe liver issues, and eye diseases.
Positive
- Upcoming Q4 and full year 2022 financial results report anticipated on March 22, 2023.
- Live audio webcast for detailed corporate and pipeline updates scheduled.
Negative
- None.
Details
News Market Reaction – SRZN
The recorded move for SRZN in the trading session of this news was +21.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress.
Interested parties may join the audio webcast via the Investor website at www.surrozen.com. To ensure a timely connection, it is recommended that individuals register at least 15 minutes prior to the start of the webcast.
About Surrozen
Surrozen is a clinical stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on inflammatory bowel, severe liver, and eye diseases. For more information, please visit surrozen.com.
Investor Contact:
Investorinfo@surrozen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.